Oyo has raised ₹1,457 crore (around $175 million) in a Series G funding round from investors like InCred Wealth, Patient Capital, and the Mankind Pharma promoters' family office. The new funds, approved by 99.99% shareholders, include ₹416 crore ($50 million) raised last month. Oyo plans to use this capital for growth, global expansion, and business enhancement. Despite the funding, Oyo’s valuation remains at $2.38 billion, a sharp 70% drop from $9.6 billion in 2021. Oyo also reported its first annual net profit of ₹100 crore in FY24.